Physician profile
Chasity Pendleton
NPI 1194586396
$2,949.85
in general payments reported to CMS, 2019-2025
26 companies · $1,541 in 2025
The $1,541 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,409 · 2025: $1,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $481.41 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $235.12 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $174.83 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $145.37 | 2024-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $142.85 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.70 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.58 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $110.86 | 2024-2025 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $105.52 | 2024-2025 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $89.03 | 2024-2025 | Trintellix |
| Corcept Therapeutics | $87.35 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $70.41 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $59.99 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.94 | 2024-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.34 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $49.27 | 2024 | Auvelity |
| Verona Pharma, INC. | $42.82 | 2025 | Ohtuvayre |
| Abiomed | $40.19 | 2025 | |
| Lundbeck LLC | $39.47 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $37.21 | 2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $37.08 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $32.65 | 2025 | Zoryve |
| Astellas Pharma US INC | $18.59 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $15.57 | 2025 | Rotateq, Capvaxive, Gardasil 9 |
| Azurity Pharmaceuticals, INC. | $15.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chasity Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.